markets
Ipsen to Acquire Kartos Therapeutics for $450 Million
French biotech company Ipsen has agreed to acquire Kartos Therapeutics for $450 million, according to Investing.com reporting on June 29, 2026.
French biotech company Ipsen has agreed to acquire Kartos Therapeutics for $450 million, according to Investing.com. The transaction was reported on June 29, 2026, though the source did not disclose additional details on deal structure, payment terms, closing timeline, regulatory approval requirements, or specific therapeutic assets included in the acquisition.
Key takeaways
Ipsen to acquire Kartos Therapeutics for $450 million, according to Investing.com
Transaction reported on June 29, 2026
Deal terms, closing timeline, and regulatory approval requirements were not disclosed in the source
Investors may watch for future company disclosures on transaction structure and strategic rationale
The source context confirmed the $450 million purchase price but did not provide further information on the strategic rationale, pipeline assets, or integration plans. For readers following broader market updates , this development reflects ongoing merger and acquisition activity in the biotech sector.
Read original source